The influence of classical prognostic factors and adjuvant chemotherapy on disease outcome in early grade 3 node-negative, and 1–3 node-positive breast cancer patients treated with adjuvant cyclophosphamide, methotrexate and fluorouracil (CMF), or untreated patients

Background. Adding taxanes to anthracycline-based adjuvant chemotherapy has shown significant improvement in node-positive breast cancer patients but the optimal dose schedule has still remained undetermined. Objectives. The feasibility of dose-dense epirubicin in combination with cyclophosphamide (EC) followed by weekly paclitaxel as adjuvant chemotherapy in node-positive breast cancer patients was investigated. Methods. All patients were treated with epirubicin (100 mg/m2) and cyclophosphamide (600 mg/m2) every two weeks for four cycles with daily Pegfilgrastim (G-CSF) that was administered 3–10 days after each cycle of epirubicin and cyclophosphamide infusion which followed by (80 mg/m2) paclitaxel for twelve consecutive weeks. Results. Sixty consecutive patients were analyzed, of whom 57 patients (95%) completed the regimen and no case of toxicity-related death was observed. Grade 3/4 hematologic toxicity was uncommon and the most common grade 3/4 nonhematological adverse event was neuropathy disorders. Conclusions. Dose-dense epirubicin and cyclophosphamide followed by weekly paclitaxel with G-CSF support is a well-tolerated and feasible regimen in node-positive breast cancer patients without serious complications.

Download Full-text

BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-10-0079 ◽

2010 ◽

Vol 16 (15) ◽

pp. 3988-3997 ◽

Cited By ~ 28

Author(s):

Charles Dumontet ◽

Maryla Krajewska ◽

Isabelle Treilleux ◽

John R. Mackey ◽

Miguel Martin ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Molecular Analysis ◽

Breast Cancer Patients ◽

Node Positive ◽

Positive Breast Cancer

Download Full-text

Gruppo Oncologico Nord Ovest – Mammella Intergruppo (GONO MIG)

Breast Cancer Online ◽

10.1017/s1470903106009205 ◽

2006 ◽

Vol 9 (S1) ◽

pp. 212-222

Author(s):

Keyword(s):

Breast Cancer ◽

Clinical Trials ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Randomized Study ◽

Phase Iii ◽

Breast Cancer Patients ◽

Node Negative ◽

Node Positive ◽

Positive Breast Cancer

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Gruppo Oncologico Nord Ovest – Mammella Intergruppo (GONO MIG). Clinical trials include: Standard CEF versus accelerated CEF as adjuvant chemotherapy in node-positive or high-risk node-negative (T > 2 cm, age <35 years, G3, negative hormone receptors or high TL1 or S-phase) breast cancer. A phase III randomized trial. MIG-1Epirubicin plus paclitaxel versus cyclophosphamide, epirubicin and 5-fluorouracil as adjuvant chemotherapy in node-positive breast cancer patients. A phase III randomized study. MIG-5A phase III randomized study of sequential epidoxorubicin plus cyclophosp-amide followed by docetaxel (EC D) versus a combination of 5-fluorouracil, epidoxorubicin and cyclophosp-amide (FEC) as adjuvant treatment of node-negative early breast cancer patients.A phase III randomized study of EC followed by paclitaxel versus FEC followed by paclitaxel, all given either every 3 or 2 weeks supported by pegfilgrastim, for node-positive breast cancer patients.Prevention of chemotherapy-induced menopause by temporary ovarian suppression with triptorelin versus control in young breast cancer patients. A randomized phase III multicenter study.Letrozole adjuvant therapy duration (lead) study: standard versus long treatment. A phase III trial in post-menopausal women with early breast cancer.

Download Full-text